Trial Profile

A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 03 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Narsoplimab (Primary) ; Narsoplimab (Primary)
Indications IgA nephropathy; Lupus nephritis; Membranoproliferative glomerulonephritis; Membranous glomerulonephritis
Focus Adverse reactions; Pharmacodynamics
Sponsors Omeros Corporation

30 Mar 2026 The protocol has been to addition in drug arms.
30 Mar 2026 Status changed from recruiting to discontinued.
01 Mar 2022 According to an Omeros Corporation media release, data were presented in the World Congress of Nephrology meeting 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com